Osimertinib and Vitrakvi
Determining the interaction of Osimertinib and Vitrakvi and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with osimertinib may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. In vitro, osimertinib has been shown to be a competitive inhibitor as well as inducer of CYP450 3A4. However, no pharmacokinetic data are available from drug interaction studies. MANAGEMENT: Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Professional:GENERALLY AVOID: Coadministration with osimertinib may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. In vitro, osimertinib has been shown to be a competitive inhibitor as well as inducer of CYP450 3A4. However, no pharmacokinetic data are available from drug interaction studies.
MANAGEMENT: Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Osimertinib-Vitrakvi (Larotrectinib Capsules)
- Osimertinib-Vitrakvi (Larotrectinib Oral Solution)
- Osimertinib-Vitrase
- Osimertinib-Vitrase injection
- Osimertinib-Vitravene
- Osimertinib-Vitron-C
- Vitrakvi-Osimertinib Mesylate
- Vitrakvi-Osmitrol
- Vitrakvi-Osmolex ER
- Vitrakvi-OsmoPrep
- Vitrakvi-OsmoPrep Oral
- Vitrakvi-Ospemifene